Centaurus: inhibiting ceramide synthesis for cardiometabolic disease
Centaurus is developing DEGS1 inhibitors to block lipotoxicity in cardiometabolic diseases
Centaurus is aiming for first-in-class small molecules that block the lipotoxicity driving cardiometabolic diseases.
Stress stimuli such as inflammation increase production of the structural lipid ceramide, which induces apoptosis, necroptosis and cellular metabolism defects.
Centaurus Therapeutics Inc.’s compounds inhibit DEGS1, an enzyme that converts dihydroceramide into ceramide, for NASH, dyslipidemia, Type II diabetes and other cardiometabolic diseases.
According to co-founder Scott Summers, the Mayo Clinic and hospitals in